Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Even with a brief drop this week, the markets are showing strength this year, with the S&P 500 climbing 8%. However, there’s a big question on investors’ minds: Can this momentum keep up? David Kostin, Goldman’s chief US equity strategist, has given four scenarios for investor consideration: “(1) in a ‘catch up,’ the S&P 500 would end the year at 5800 (+12% from today), (2) in a ‘catch-down,’ the S&P 500 would fall to 4500 (-14%), (3) continued mega-cap exceptionalism would lift the index to 600
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4.
Olema Oncology Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.